Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Treasury Shares (2016 - 2025)

Historic Treasury Shares for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to $63.4 million.

  • RedHill Biopharma's Treasury Shares rose 8227.4% to $63.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $63.4 million, marking a year-over-year increase of 8227.4%. This contributed to the annual value of $35.0 million for FY2024, which is 6340.66% up from last year.
  • As of Q2 2025, RedHill Biopharma's Treasury Shares stood at $63.4 million, which was up 8227.4% from $35.0 million recorded in Q4 2024.
  • RedHill Biopharma's Treasury Shares' 5-year high stood at $63.4 million during Q2 2025, with a 5-year trough of $1.3 million in Q1 2021.
  • Over the past 5 years, RedHill Biopharma's median Treasury Shares value was $2.3 million (recorded in 2022), while the average stood at $12.5 million.
  • In the last 5 years, RedHill Biopharma's Treasury Shares soared by 1504.97% in 2022 and then surged by 65629.63% in 2023.
  • Over the past 5 years, RedHill Biopharma's Treasury Shares (Quarter) stood at $1.5 million in 2021, then skyrocketed by 89.63% to $2.8 million in 2022, then skyrocketed by 656.3% to $21.4 million in 2023, then surged by 63.41% to $35.0 million in 2024, then soared by 80.97% to $63.4 million in 2025.
  • Its Treasury Shares stands at $63.4 million for Q2 2025, versus $35.0 million for Q4 2024 and $34.8 million for Q2 2024.